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The Centre for Health Economics Research and Evaluation (CHERE) was established in 1991.
CHERE is a centre of excellence in health economics and health services research.  It is a joint
Centre of the Faculties of Business and Nursing, Midwifery and Health at the University of
Technology, Sydney, in collaboration with Central Sydney Area Health Service.  It was established as a
UTS Centre in February, 2002.  The Centre aims to contribute to the development and application of
health economics and health services research through research, teaching and policy support.
CHERE’s research program encompasses both the theory and application of health economics.  The
main theoretical research theme pursues valuing benefits, including understanding what individuals
value from health and health care, how such values should be measured, and exploring the social
values attached to these benefits.  The applied research focuses on economic and the appraisal of
new programs or new ways of delivering and/or funding services.
CHERE’s teaching includes introducing clinicians, health services managers, public health
professionals and others to health economic principles.  Training programs aim to develop practical
skills in health economics and health services research.
Policy support is provided at all levels of the health care system by undertaking commissioned
projects, through the provision of formal and informal advice as well as participation in working
parties and committees. FOREWORD
This project was commissioned by the National Breast Cancer Centre (NBCC). The objectives of the
project, as set out in the call for expressions of interest, were to determine:
> The costs associated with the introduction and use of directional vacuum-assisted breast biopsy
(DVA breast biopsy) in Australia; and 
> Whether directional vacuum-assisted breast biopsy used for diagnostic purposes is cost-effective
in Australia when compared to core biopsy. 
The motivation for commissioning the project was an assessment of directional vacuum-assisted
breast biopsy conducted by the Medical Services Advisory Committee (MSAC) which concluded that
the procedure is safe and more effective than core biopsy. Although a cost-effectiveness analysis was
not conducted as part of the MSAC study, MSAC recommended that the costs associated with the
procedure be investigated and that, pending a review of costs, the procedure receive interim Medicare
funding at a higher level than was previously available.
For the project reported here, data was required to be collected from both public and private sectors
on the cost of introducing and using DVA breast biopsy and a cost-effectiveness analysis (CEA)
conducted on the introduction and use of DVA breast biopsy with and without a prone table. The
research question for the CEA was
> What is the impact on costs and number of open biopsies performed of using DVA breast biopsy
compared to core biopsy for micro-calcification lesions?
It is important to note that this question specifies both the outcome the CEA (change in the number
of core biopsies performed) and that the investigation was to be confined to micro-calcification
lesions only. 
An expert multidisciplinary working group was assembled to oversee the project.
Following collection of data an interim report was produced for the working group. As DVABB is a
relatively new technology in Australia the interim report indicated that the current number of sites
performing DVABB and the level of experience of users was insufficient to provide meaningful data to
achieve the project aims.  On the advice of the working group it was agreed to suspend the project at
this juncture. The NBCC will consider repeating the survey in the future.
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1. INTRODUCTION
Directional vacuum assisted (DVA) breast biopsy is a relatively new technology used to aid in the
diagnosis of suspicious breast lesions including microcalcifications, masses, speculated masses,
asymmetric multifocal disease and diffuse tissue (Medicare Services Advisory Committee 1999). 
This technology is currently used in a number of BreastScreen centers and Private clinics 
across Australia. 
The primary advantages of DVA breast biopsy over open biopsy are:
> less invasive  procedure, leading to less pain and  quicker recovery time for the patient; and
> decreased chance of  breast disfigurement (ref??).
The primary advantages of DVA breast biopsy over core biopsy are:
> the ‘vacuum chamber actively draws tissue into the collection chamber … rather than relying on
tissue recoil to fall on the collection chamber’ (Vargas, Agbunag et al. 2000, p. 375)
> larger and better quality samples {Vargas, 2000 #24}and {Wong, 2000 #23};
> the ability to obtain multiple specimens without having to remove and reinsert the needle (this is
due to the directional capability of DVA technology) {Vargas, 2000 #24}and {Trevathan-Ramirez,
1998 #1}; and
> the potential to remove all microcalcifications (Trevathan-Ramirez 1998).
There is currently very little international evidence and no published Australian evidence on the cost-
effectiveness of DVA breast biopsy technology. In an effort to fill this gap CHERE was commissioned
by iSource – The National Breast Cancer Centre - to evaluate the cost-effectiveness of DVA breast
biopsy technology in the diagnosis of microcalcifications. In this study, DVA and core breast biopsy
technologies were compared in terms of both costs and effectiveness. 
This report presents:
> results from an international literature review on the effectiveness and cost-effectiveness of DVA
breast biopsy;
> information on the collection of data on DVA and core biopsy, including survey procedure and
response rates; 
> an investigation of the effectiveness data; and
> a discussion based on the available data.2. INTERNATIONAL LITERATURE REVIEW OF DVA 
BREAST BIOPSY TECHNOLOGY
The aim of this literature review was to identify studies which had evaluated either the effectiveness
or cost effectiveness of DVA breast biopsy technology. A search was conducted using the Medline and
Embase databases. The search for articles on the ‘effectiveness’ of DVA breast biopsy technology was
restricted to the years 1998-2002 while the search for articles on the ‘cost effectiveness’ of DVA
breast biopsy technology was limited to the years 1995-2002. The literature review was also limited to
studies which evaluated the effectiveness of DVA breast biopsy under stereotactic guidance. Studies
which evaluated vacuum assisted breast biopsy under the guidance of ultrasound were excluded as it
is known that the type of guidance used, particularly in the detection microcalcifications, impacts
directly on the accuracy of tissue retrieval and hence, diagnostic accuracy (Vargas, Agbunag et al.
2000) and (Lattanzio, Guerrieri et al. 2001).  
2.1 Main findings from the literature review of DVA breast biopsy 
Eighteen studies were found to have evaluated the effectiveness of DVA breast biopsy techniques.
Randomised control trials are generally recognised as ‘the study type of choice when the objective is
to evaluate the effectiveness of a treatment or procedure (Dawson and Trapp 2001, p.304)  . No
studies identified in this search were randomised control trials. The studies identified consisted of
prospective observational studies and retrospective reviews. These types of studies provide weaker
levels of evidence than a randomised control trial.
Furthermore, the results of all studies are not directly comparable because of different study design
features including;
> ‘effectiveness’ was measured in a number of different ways, including successful sampling,
accuracy of diagnosis, surgical procedure/s spared and re-biopsy rates;
> confirmation of diagnoses was not measured in the same way across all studies; 
> the type of lesions biopsied differs between studies; and 
> the length of follow up differed.
These factors should be kept in mind when reviewing the results presented in this section. Study
characteristics including effectiveness measured employed, diagnosis confirmation method/s and
follow up period (where applicable) have been summarised in Appendix A.
2.1.1 Effectiveness of the DVA breast biopsy systems
DVA breast biopsy techniques appear to be an effective breast biopsy technique in terms of tissue
sampling, diagnostic accuracy and sparing surgical procedures (particularly when an 11 gauge
needle is used) (see Table 1). A further advantage of DVA breast biopsy is the low complication rates
associated with the procedure, particularly when the procedure is done in the prone position.
However, there has been little replication of available studies. This may be due to the broad range of
possible effectiveness measures available for us in this context as well as the diverse range of lesions
which this procedure can be used to diagnose.
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Table 1. Summary of ‘effectiveness’ estimates for DVA breast biopsy
EFFECTIVENESS MEASURE RANGE OF VALUES OBTAINED FROM REVIEW
Successful sampling All lesions (8, 11and/or 14) gauge: 96.4 -100%
Calcification:  96.3 - 100%
Diagnostic accuracy All lesions 11 and/or 14 gauge: 80 – 100%
Benign lesions: 99%
Non- benign lesions: 95%
Calcifications 11 gauge: 98%
Calcifications 14 gauge: 91%
Sensitivity All lesions 11 gauge: 87.5%
Breast carcinoma 8 and 11 gauge: 88 -98%
Diagnostic underestimation Calcification: 16.3%
Cancer: 9.5%
Masses: 1.6%
Ductal carcinoma in situ: 0 -18%
Surgical procedure spared 11 gauge: 76.6%
14 gauge: 35.3%
11 and 14 gauge: 46%
Complication rate Approximately 1- 4% prone unit
Approximately 5% upright unit 
Velanovich et al (1999) directly compared the results of DVA breast biopsy with core needle biopsy,
advanced breast biopsy instrumentation (ABBI) and wire localised biopsy for women with suspicious
mammograms. The results of this study showed that DVA performed well when compared with
other forms of breast biopsy (see Table 2). Although the performance of ABBI was found to be better
than DVA and core biopsy, not all women will meet the criteria identified by the authors for use of
ABBI, which includes:
> breast thickness greater than 30mm thick when compressed;
> lesion less than or equal to 1cm in diameter; and
> lesion must be greater than or equal to 1 cm from the chest wall and skin.
Patient criteria for core and DVA breast biopsy was identical and less stringent than patient criteria
for ABBI. Therefore, core biopsy appears to be a more useful comparator than ABBI for DVA breast
biopsy. When DVA breast biopsy was compared with core biopsy in this study, DVA was found to be
the more effective option.
Table 2. Summary of effectiveness results for alternative breast biopsy techniques*
EFFECTIVENESS MEASURE DVA CORE BIOPSY ABBI
%%%
Technical success 96.4 94.3 98.7
Sensitivity 87.5 87.5 100
Specificity 100 98.6 100
Discordant result/need for rebiopsy 23.2 25.7 7.5
* Figures in this table have been taken from the study by Velanovich et al (1999)2.1.2 Accuracy of 11 versus 14 gauge needle
DVA breast biopsy has typically been undertaken with either a 14 or 11 gauge needle. The specimen
obtained through the use of an 11 gauge needle is much larger than that obtained with a 14 gauge
needle, at approximately 95mg vs. 18mg respectively (Gray, Benson et al. 1999). Therefore, it can be
hypothesized that, due to the larger size of sample collected,  a breast biopsy undertaken with an 11
gauge needle should reduce the rate of sampling error and hence reduce the diagnostic error rate.
Three studies were found to have compared the results of DVA breast biopsy undertaken with 11
gauge and 14 gauge needles. The results of these studies are presented in Table 3. (See Appendix 1
for a more detailed presentation of study features.) Based on the results from the limited number of
studies available, the use of an 11 gauge needle appears to be more effective than a 14 gauge needle
when effectiveness is defined in terms of successful sampling, diagnostic accuracy and surgical
procedures avoided. 
Table 3. Comparison of results from 11 and 14 gauge DVA breast biopsy studies
AUTHOR ‘EFFECTIVENESS’  RESULTS
Liberman, Gougoutas et al (2001) % surgical procedure avoided 11 gauge: 76.6%
% surgical procedure avoided 14 gauge: 35.5%
Berg, Arnoldus et al (2001) Accuracy 11 gauge: 98%
Accuracy 14 gauge: 91%
Nisbet et al (1999) Successful sampling 11 gauge: 86%
Successful sampling 14 gauge: 62%
2.1.3 Upright versus prone units
DVA breast biopsy techniques can be used with the patient in either an upright or prone position. The
advantages of undertaking DVA breast biopsy in the prone position, as opposed to the upright
position include:
> reduced incidence of vasovagal reactions (Georgian-Smith, D'Orsi et al. 2002);
> reduced likelihood of patient movement throughout the procedure; and
> quicker examination completion (Bassett, Winchester et al. 1997)
However, the upright unit is cheaper and requires less space than a dedicated prone biopsy table
(Nisbet, Borthwick-Clarke et al. 2000).
Three studies were found to have evaluated the effectiveness of DVA breast biopsy when conducted
with an upright unit (See Table 4). As a range of different needle gauges (8, 11 and 14 gauge) were
used in these studies care must be taken when comparing results. 
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Table 4. Summary of DVA breast biopsy effectiveness with an upright unit
AUTHOR DVA NEEDLE GAUGE STUDY POPULATION RESULTS
Georgian  8 and 11 gauge N= 180 biopsies  - Successful sampling in 98%
–Smith, D’Orsi  in 174 patients - Discordant results: 4% (4 cases benign at core 
et al  (2001) N=156 (11 gauge)  biopsy were malignant at surgical pathology 
N= 24 (8 gauge) and 2 malignant cases were underestimated)
Ohsumi et al 11 and 14 gauge N=88 lesions  - With surgical diagnosis: 80% accuracy
(2001) in 86 patients (5 lesions underdiagnosed, 1 lesion 
N= 85 (11 gauge) 1 lesion overdiagnosed)
N= 3 (14 gauge) - All benign lesions followed up without event.
Nisbet et al (1999) 11 and 14 gauge N= 21 (14 gauge) - Successful sampling 11 gauge: 86%
N= 21 (11 gauge) - Successful sampling 14 gauge: 62%
Overall, successful sampling was estimated to have occurred in approximately 62-86% of cases
(Georgian-Smith et al 2000 and Nisbet et al 1999). When results obtained with a 14 gauge needle are
excluded the range is considerably smaller, with successful sampling estimated to have occurred in
86-98% of cases (Georgian-Smith et al 2000 and Nisbet et al 1999). Discordant results were
estimated to occur in approximately 4-20% of cases. Georgian–Smith et al (2001) found that in their
sample (N=180) 4 cases which were diagnosed as benign at the time of core biopsy were found to be
malignant when surgical pathology was undertaken. Two malignant cases were also found to be
underestimated (Georgian-Smith 2001). The types of lesion/s diagnosed in this study were not
specified. Ohshumi et al (2001) found that within their sample (N=88) 5 lesions were under diagnosed
and 1 lesion was over diagnosed. 
The results of these studies, in terms of sampling success and diagnostic accuracy, appear to be
similar to the results found for DVA breast biopsy when conducted on a prone table. However, at this
stage, due to the limited number of studies available it is difficult to draw strong conclusions about
the relative effectiveness of biopsies undertaken using an upright unit compared with those
undertaken using a prone table. 
2.1.4 Total vs. partial lesion removal
Only a handful of studies have sought to assess the relative effectiveness of partial lesion removal
versus total lesion removal, and the evidence that does exist is conflicting. In studies conducted by
Philpotts et al (2000) and Liberman, Smolkin et al (1998) it was found that diagnostic accuracy
improved from 84% and 98% respectively when the lesion was only partially removed, to 100% with
complete lesion removal. However, Liberman, Kaplan et al (2002) found that ‘complete excision
rather than sampling of the mammographic target yielded no significant differences in the frequency
of sparing surgery, atypical ductal hyperplasia underestimates, rebiopsy or complications (p.679)’.
These studies suggest that further investigation is warranted to determine whether there is a
significant difference in ‘effectiveness’  between partial and complete lesion removal, and whether
there are certain types or sizes of lesions where complete lesion removal may be recommended over
partial lesion removal or vice versa. 5
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2.1.5 Reasons for errors in DVA breast biopsy
Although sampling error rates for DVA breast biopsy technology are small they do exist. The primary
reasons for errors in tissue retrieval were summarised by Heywang-Kobrunner et al 1998, (p381) and
are outlined below:
> miscalculation of lesion depth due to identification of different structures on the ±15-  stereotaxic
views for error in the depth calculation due to slight accuracy in the stereotaxic planning on the
±15- view;
> deviation of the needle within dense tissue;
> patient movement;
> high elasticity of certain tissues which may be pushed forward instead of being penetrated by the
needle; and
> acquisition of nonrepresentative tissue due to discontiguous growth of certain malignancies (ie.
sampling error), for example in situ carcinomas and some lobular carcinomas.
Heywang-Kobrunner et al (1998) believe that to limit the number of errors the radiologist should
‘undertake a critical review of all results of percutaneous biopsy together with imaging findings ie.
whenever imaging findings were considered suspicious and disagreed with a benign histology or
cytology, a repeat or open biopsy remained necessary (p.381).’
2.1.6 The role of experience in technical success
One study was identified which evaluated the impact of a radiologists experience on the technical
success rate and false negative rate of stereotactic DVA breast biopsy. The study found that the
technical success rate (using an 11 gauge needle) was significantly lower in the first five cases that
were undertaken than subsequent cases and this finding was also true when the technical success
of the first 15 cases was compared to subsequent cases (see table 5).  For biopsies undertaken with
both 11 and 14 gauge needles the learning curve was found to be steeper for microcalcifications than
for mass lesions, but overall the authors concluded that the learning curve for stereotactic breast
biopsy is relatively short. It should be noted that as academic radiologists who specialised in breast
imaging participated in this study and hence, the generalisability of results to different settings may
be limited. 
Table 5. Learning curves for stereotactic breast biopsy
FIRST 5 CASES VS. SUBSEQUENT CASES FIRST 15 CASES VS. SUBSEQUENT CASES
11 gauge needle
- Technical success rate 85% (17/20) vs 96.3%(310/322) 90% (54/60) vs 96.5% (273/283)
- False-negative rate N/A 7.4% ( 2/27) vs. 0% (0/85)
14 gauge needle
- Technical success rate N/A 91.7% (55/60) vs. 97.9% (92/94)
- False negative rate N/A 4.8% (1/21) vs. 0% (0/31)6
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2.2 Cost effectiveness of DVA breast biopsy techniques – literature review findings
In a true cost effectiveness study the relative costs of two interventions are weighed up against the
relative effectiveness of the interventions. Based on this definition no true cost effectiveness studies
evaluating DVA breast biopsy were identified in this literature search. At this stage there is no
information on the cost effectiveness of DVA breast biopsy technology. 
However, two studies were identified which included costings associated with DVA breast biopsy. The
main features of these studies are outlined in Table 6 (see next page).  In these studies DVA was
found to result in savings of between $264 (A$360) - $334 (A$445) per diagnosis. However, a number
of study limitations have been identified which should be kept in mind when reviewing these results.
The main limitation of the study by Liberman and Sama (2000) was the retrospective nature of the
study which makes it less likely to be able to capture all costs associated with the procedures
evaluated. The study by Liberman, Gougatas et al (2001) was limited by the fact that the study groups
was not randomised, data collection was not blinded and the costs included in this study were not
well reported. At best, these studies provide us with some information on the relative costs
associated with DVA and core biopsy.
Table 6. Main study features of DVA breast biopsy cost effectiveness evaluation
Author  Liberman and Sama (2000) Liberman, Gougoutas et al. (2001)
DVA specifications - 11 gauge  - 11 and 14 gauge
- prone table - prone table
Comparator Surgical biopsies Surgical biopsies
Intervention type Diagnosis Diagnosis
Lesion type Non-palpable lesions Calcifications highly suggestive of malignancy
Effectiveness measure Surgical biopsies obviated Surgical procedures spared
Study population N= 200  N= 17 (14 gauge)
(154 with calcification lesions) N= 47 (11 gauge)
Results Surgical biopsies obviated: Surgical procedure spared:
- Total : 76% (151/200) -  11 gauge: 76.6% ( 36/47)
- Microcalcifications: 73% (112/154) -  14 gauge: 38.1% (16/42)
Mean adjusted direct cost savings per Cost savings of $334 per diagnosis
diagnosis $264 (ie. a 20% decrease in (ie. 20% decrease in the cost per diagnosis)
the cost per diagnosis.)7
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3. INVESTIGATION OF THE EFFECTIVENESS DATA 
This section presents the results from data collection for this study. In this round of data collection we
were primarily interested in collecting information on the effectiveness of DVA and core biopsy in the
diagnosis of microcalcifications. Effectiveness in this study was defined as ‘the number of open
biopsies avoided’.
3.1 Data retrieval
3.1.1 Data retrieval: Survey 1 
Twenty five centres known to have DVA technology available for breast biopsy were surveyed to obtain
information on the effectiveness of both DVA and core biopsy. One additional centre was included in
the sample after it had indicated that DVA breast biopsy technology was used in their centre (This
centre was initially surveyed for information on core biopsy only).  Of the 26 centres surveyed, 15
surveys were returned, 5 centres indicated they were unable to complete the survey (typically
because they had not used the technology in the study period or had not used it for
microcalcifications), 5 centres failed to return any calls and 1 centre has indicated that it will complete
the survey but has not responded to a request for a date by which they will return the survey. 
Of the 15 surveys that were returned 3 surveys could not be used in calculating effectiveness as the
appropriate section was not complete. In the first survey, this section had not been attempted at all
and as there were no details about which centre this survey belonged to it could not be followed up.
In the second survey blank spaces were left in a number of boxes and it was unclear whether this
represented non-completion or zeros. A follow-up phone call was made to this centre to clarify their
results. It was found that this centre does not perform the ‘initial’ screening of women and the centre
does not manage the treatment of women if a repeat biopsy is needed. Therefore, as the information
contained in this survey was not consistent with the requirements of this study, data from this centre
were excluded from the sample. In the third survey, the respondent indicated that the effectiveness
section had been completed for all biopsies not just microcalcifications (as was specified in the
question). An enquiry was made about whether this centre had data available for microcalcifications
only, but to date there no response has been received. Therefore, overall 12 surveys were used to
obtain information on the effectiveness of DVA biopsy (Centres 1-12).
3.1.2 Data retrieval: Survey 2
Six centres which did not have DVA technology but undertake core biopsies were also surveyed to
provide additional information on the effectiveness of core biopsy. Responses were received from 5 of
the 6 centres. One centre indicated that they were not able to complete the survey, leaving 4
additional surveys to use (Centres 13-16).  Nine centres which had previously completed the survey
for DVA biopsy also provided information on the effectiveness of core biopsy (Centres 2-8 and 11-12).
Therefore, a total of 13 survey responses were obtained regarding the effectiveness of core biopsy.
3.2 Maximising response rates to surveys
Two surveys were sent out in the first round of data collection. Survey 1 was sent to 25 centres known
to have DVA breast biopsy technology, to collect information on both DVA and core biopsy. Survey 2
was sent out to 6 centres which were believed to undertake core biopsy only, to collect additional
information on core biopsy. Both surveys were accompanied by a letter from the National Breast
Cancer Centre (NBCC) which briefly explained who was involved in the study and asked centres to
participate. A letter from CHERE which briefly explained the project and CHERE’s role in the project
was also sent out with each survey. 8
CENTRE FOR HEALTH ECONOMICS RESEARCH AND EVALUATION
To improve the response rate, reminder letters were sent to all centres which had not responded to
either CHERE or the NBCC by the due date. After what was considered to be a reasonable period,
follow up calls were made to centres which had still not responded or had indicated that they needed
more time to complete the survey. Centres were once again given what was thought to be a
reasonable period to respond, and following this, centres which had indicated that they would return
their survey but had not done so and centres which had not returned calls were phoned again. The
timing of calls varied, depending on how a centre had responded previously, whether the centre had
indicated it needed more time and/or specified how much more time was needed.
It appears that the centres surveyed understood that the data requested was for microcalcifications
only as;
> the cover letter provided by CHERE indicated that the study was for the diagnosis of
microcalcifications only;
> all effectiveness questions in the survey specifically referred to microcalcifications, with
‘microcalcifications’ or ‘microcalcifications only’ typed in bold to highlight this; and perhaps 
most importantly
> individuals from a number of centres who contacted us indicated that it would be difficult and/or
more time consuming to retrieve the information on microcalcifications only (hence their request
for more time). This indicates that it was clear to centres that microcalcifications were the lesion
of interest.
3.3 Sample characteristics of the biopsy data
The data were examined to investigate the representativeness and reliability of the sample. It should
be noted that not all centres that performed DVA breast biopsy also performed core biopsy, and vice
versa. Therefore, to identify which procedures individual centres undertook, each centre was
assigned a number (from 1-17) and these numbers were used as X-axis labels in Figures 1 and 2
below to indicate which centres undertook the procedure of interest. Therefore, centres can 
be identified as using DVA and core biopsy if their number is present in both Figures 1 and 2 
(eg. Centre 2). Centres which used either DVA or core biopsy only are represented in the appropriate
figures (eg. Centre 1 undertook DVA biopsy only and Centre 12 undertook core biopsy only.)
The data for DVA breast biopsy was examined first. An important characteristic of the sample data is
the wide variation in the number of DVA breast biopsies performed across centres in 2001; figures
ranged from 3 -151 (see Figure 1). In some centres, DVA breast biopsy technology does not appear to
have been widely used, ie. less than 10 DVA breast biopsies were performed in some centres
throughout 2001. This is of concern as Liberman, Benton et al (2001) found that a learning curve
exists for DVA breast biopsy technology, with ‘significantly higher technical success rates and lower
false-negative rates’ observed after the first 15 cases of DVA breast biopsy. Three of the centres in
our sample had performed fewer than 15 DVA breast biopsies and therefore, in light of the evidence
from Liberman, Benton et al (2001) we are less confident about the effectiveness results for these
centres. If these centres are excluded our sample becomes smaller, and would be based on the
results from 9 centres.9
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Figure 1. Number of DVA biopsies performed by centre
The data for core breast biopsy were also examined. Almost all centres in the sample had performed
a reasonable number of core biopsies over the study period, with only one centre performing a
relatively low number of biopsies (N=13) (see Figure 2).This data point was not excluded from the
sample as core biopsy has been used in practice for a sufficiently long period and, it therefore seems
reasonable to assume that ‘learning’ would have taken place in this centre. 
Figure 2. Number of core biopsies undertaken by centre
The relationship between the number of DVA biopsies undertaken in a centre and the level of
effectiveness was also investigated. Effectiveness in this study was defined as the number of open
biopsies avoided (sometimes referred to as the pre-operative diagnosis rate). When the number of
biopsies was plotted against the level of individual centre effectiveness it can be seen that most of the
results are clustered towards the right hand side of the scale, with effectiveness levels of greater than
80%, regardless of the number of DVA biopsies performed (see graph 1). However, there is one data
point which appears to be very different to the rest of the data. This data point represents a centre
where only three DVA breast biopsies were undertaken, which subsequently resulted in 2 open
biopsies being performed. Therefore, effectiveness for this individual centre was measured at 33% - a
markedly different result to the rest of the sample. However, there do not appear to be any grounds
for excluding these data from the sample. When the number of core biopsies is plotted against





































































































sGraph 1. Relationship between number of DVA biopsies performed and centre effectiveness
Graph 2. Relationship between number of core biopsies performed and centre effectiveness
In the initial project proposal CHERE proposed that additional centres would be contacted if the data
for core biopsy were insufficient. However, this was not thought to be necessary as the data collected
on core biopsies appeared to be sufficient, primarily because the total sample size was relatively
large. All centres - except one - which completed this section of the survey had performed over 30
core biopsies, and the effectiveness results from the centres surveyed were consistent, that is there
were no obvious outliers or ‘odd’ results. 
3.4 Alternative measures of effectiveness and results
In this study effectiveness is measured as the number of open biopsies avoided. Different methods
for calculating the level of effectiveness, the appropriateness of different methods and results
obtained from each method are outlined below.
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s3.4.1 Effectiveness based on total number of biopsies
Effectiveness can be calculated by adding the total number of DVA’s, core biopsies and open biopsies
performed across all centres and calculating the relevant measures of effectiveness. In our sample
the total number of DVA breast biopsies performed in 2001 was 562. Of these biopsies, 46 open
biopsies were subsequently performed. The total number of core biopsies performed in our sample
was 1,483 and 142 open biopsies were subsequently performed. Effectiveness measures based on
this methodology are presented in Table 2.
Table 2. Effectiveness based on totals
SAMPLE EFFECTIVENESS (%)
DVA breast biopsy
- All centres included 91.8
- ‘Under 15’ biopsies excluded 91.9
Core biopsy 90.4
3.4.2 Effectiveness based on average centre effectiveness
Alternatively, effectiveness can be measured by calculating the level of effectiveness for each centre
and from this, calculating an overall average measure of effectiveness across the sample. Results
using this methodology are shown in Table 3. 
Table 3. Effectiveness based on centre effectiveness
SAMPLE EFFECTIVENESS (%)
DVA breast biopsy
- All centres included 89.2
- ‘Under 15’ biopsies only included 93.0
Core biopsy 91.0
An important aspect of this methodology is that each centre contributes equally to the measure of
effectiveness. This is an important limitation of this method as, for example, a centre which
performed 3 DVA breast biopsies is allocated the same weight as a centre which performed 138
biopsies. Furthermore, as the effectiveness of the technology appears to be a function of experience
(Liberman, Benton et al 2001) this measure does not appear to be adequate. Therefore, a weighted
measure of effectiveness would be more appropriate.
3.4.3 Weighted effectiveness
The preferred measure of effectiveness is one that weights the level of effectiveness achieved by each
centre according to the number of DVA or core biopsies that were performed in that centre, relative
to the total number performed in the whole sample. This methodology is the most appropriate to use
because it takes into account the wide variation in the number of biopsies performed across centres.
Weighted effectiveness results are presented in Table 4.
Table 4. Weighted effectiveness
SAMPLE EFFECTIVENESS (%)
DVA breast biopsy
- All centres included 91.8
-  ‘Under 15’ biopsies only included 91.9
Core biopsy 90.4
When effectiveness measures are calculated using the preferred methodology (weighted
effectiveness) and the most appropriate sample of centres (under 15 biopsies and incomplete data
excluded) DVA biopsy (91.9%) is found to be only slightly more effective than core biopsy (90.4%). This
finding seems to hold no matter what method is used to calculate effectiveness. 
11
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The effectiveness results outlined in Section 3 indicate that there is no real difference in the
effectiveness of DVA and core biopsy and this has implications for the study. A cost-effectiveness
analysis is only justified if differences exist in both the costs and effectiveness of two health care
interventions. As this is not the case here, a cost effectiveness analysis would be inappropriate.
Rather, a cost-minimisation analysis (which assumes equal effectiveness across technologies) would
be the appropriate analysis to undertake. The aim of a cost minimisation analysis is to cost each
procedure – in this case DVA and core biopsy- to establish which procedure is least costly, the
magnitude of cost differences between the two procedures, and to determine what aspects of the
procedures drive cost differences. 
Based on survey results and expert opinion, it appears that the major driver of cost differences
between DVA and core biopsy is the cost of the biopsy equipment (ie. the Mammotome and Bard
Biopsy gun) and associated equipment consumables (eg. biopsy needle). The number and type of
staff required to perform the procedures, staff time, patient consumables and pathology associated
with both procedures appear to be very similar and would not affect relative costs. Therefore, as it is
clear which resources are the primary drivers of cost differences between the procedures, a formal
cost minimisation is also unnecessary as it would be unlikely to produce additional understanding of
differences in costs between the two procedures. The members of the NBCC project team agreed
that the formal costing component of this study would not proceed. 
It may be too early to undertake a cost-effectiveness study of the type attempted here (ie. where
effectiveness is based on a sample of centres utilising the technology for a particular reason) as the
diffusion and application of DVA technology in Australia appears to be in its early stages.  In these
circumstances a randomised controlled trial (RCT) is the preferred study design. Data obtained in an
RCT on the effectiveness of both DVA and core biopsy could be used in a cost-effectiveness analysis,
either in tandem with the RCT or as a separate, subsequent study. An appropriately conducted RCT
would not be affected by the low level of diffusion and would be able to deal with factors such as level
of experience of centres, patient characteristics (to ensure a random sample) and other
environmental factors which could not be controlled for in this study. This option is suggested for
consideration by the NBCC project team.
12
CENTRE FOR HEALTH ECONOMICS RESEARCH AND EVALUATIONLIST OF APPENDICES
Appendix 1: Summary table for DVA breast biopsy diagnostic effectiveness literature
Appendix 2: Survey 1: DVA and core biopsy
Appendix 3: Reminder letter sent out to all centres
Appendix 4: Survey 2: Core biopsy only
13
EVALUATION OF DIRECTIONAL VACUUM-ASSISTED BREAST BIOPSY: REPORT FOR THE NATIONAL BREAST CANCER CENTRE14
CENTRE FOR HEALTH ECONOMICS RESEARCH AND EVALUATION
APPENDIX 1
Table 1. Summary of DVA breast biopsy diagnostic effectiveness literature
AUTHOR DVA LESION STUDY EFFECTIVENESS RESULTS






Solitary lesions N= 788 (466 lesions























- 11 gauge (n=47)
-14 gauge (n=17)
Medical records reviewed





- 11 gauge: 76.6%
- 14 gauge: 35.3%
(Berg, Arnoldus
et al. 2001)





clearly stable for at
least 5 years and




- 14 gauge (n=11)
Mammographic follow up





- Accuracy 11 gauge: 98%
- Accuracy 14 gauge: 91%
- Surgical procedure






Suspicious lesions N=315 biopsies with
adequate follow-up
Follow up 6 month
mammogram
- Accuracy rate for benign
and non benign lesions:
97.9%  (2 misses)
- Accuracy rate for benign
lesions: 99%











- N= 35 (8 gauge)
Surgical pathologic results
of 104 breast carcinomas
reviewed.
Underestimation of invasive
carcinoma of DCIS lesion:
- < 30mm (11 gauge): 3%
- > 30 mm (11 gauge): 43%
- < 30 mm (8 gauge): 0%
- > 30 mm (8 gauge): 17%
Sensitivity for diagnosis of
breast carcinoma:
- 11 gauge: 89%
- 8 gauge: 96%15








Not specified N= 180 biopsies in 174
patients




Follow up occurred in 147
cases
- Successful sampling 
in 98%
- Discordant results: 4% (4
cases benign at core
biopsy were malignant at


















N=88 lesions in 86 patients
N= 85 (11 gauge)
N= 3 (14 gauge)
Surgical diagnosis for




- With surgical diagnosis:
80% accuracy (5 lesions
underdiagnosed, 1 lesion
overdiagnosed)
- All benign lesions



















diagnosis had 6 month
follow up mammogram.
- Patients who were
followed up (67%)
showed no change in
cluster development 
or new areas of
calcification or densities.
- Underestimation rate for
carcinoma: 20% (2/10)















N= 56 lesions surgically
excised lesions
Pathology of DVA and
surgically excised tissue of
56 carcinomas as well as
imaging findings
correlated.
- Sensitivity for diagnosis
of invasion in breast
cancer: 88%










a mass or density)













Table 1. Summary of DVA breast biopsy diagnostic effectiveness literature (continued)
AUTHOR DVA LESION STUDY EFFECTIVENESS RESULTS
SPECIFICATIONS TYPE POPULATION MEASURE









N=594 lesions in 560
patients
All borderline, DCIS or
invasive carcinoma cases
reexision performed.
All patients followed up 
6-12 months.
- Accuracy: 100% (N=117)
- Complete removal in
95% of cases with
microcalcifications
<1cm and 46% of
masses <1cm.
- For lesion >1 complete
removal was not
attempted.16
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Table 1. Summary of DVA breast biopsy diagnostic effectiveness literature (continued)
AUTHOR DVA LESION STUDY EFFECTIVENESS RESULTS
SPECIFICATIONS TYPE POPULATION MEASURE
(Philpotts, Lee et
al. 2000)
- 11 gauge 
- prone table
Retrospective review
to identify cases of
atypical ductal
hyperplasia, ductal
carcinoma in situ, or
invasive diseases
N= 178 Accuracy defined as those
where histologic diagnosis
from excisional biopsy was
the same or at a lower
stage than DVA biopsy.
- Overall rate of 
accuracy: 90.5%
- Rate of underestimation
for cancer: 9.5%
- Underestimation rate for
calcification: 16.3%
- Underestimation rate 
for masses: 1.6%
- Underestimation rate 













N= 107 - Technical success: if
enough tissue had been
removed to produce
pathologic diagnosis









- Technical success: 96.4%
- Sensitivity (true positive):
87.5%
- Specificity (true negative):
100%












findings 6 month follow up.
- No cases of false
negative biopsies
















N= 21 (14 gauge)
N= 21 (11 gauge)
Successful sampling of
calcifications
- Successful sampling 11
gauge: 86%
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(Zannis and
Aliano 1998)
- 11 gauge and
14 gauge
- prone table
Breast lesions N=72 6 month mammogram
follow-up for benign
































- Sensitivity: 99% (2 cases
(1%) where stereotaxic
depth was incorrect)
- In borderline lesions, in
situ carcinoma, and
invasive carcinomas no
change in diagnosis with
re-exision or
mastectomy
- Complete removal of
lesion (although not a




and 19/20 for densities
>1cm




















Table 1. Summary of DVA breast biopsy diagnostic effectiveness literature (continued)
AUTHOR DVA LESION STUDY EFFECTIVENESS RESULTS
SPECIFICATIONS TYPE POPULATION MEASUREAPPENDIX 2
Study background
This aim of this study is to assess the cost-effectiveness of stereotactic vacuum assisted breast
biopsy in the diagnosis of microcalcifications. In this study the cost-effectiveness of vacuum assisted
(mammotome) breast biopsy will be compared against stereotactic core biopsy. Therefore, the
information in this questionnaire focuses on stereotactic vacuum assisted breast biopsy
(mammotome) and stereotactic core biopsy in the diagnosis of microcalcifications.
General questions for vacuum assisted breast biopsy cost effectiveness study
1. How long has your service had vacuum assisted (mammotome) breast biopsy equipment?
2. How many vacuum assisted (mammotome) breast biopsy systems does your service have?
3. Does your service have a prone table? If not, what type of stereotactic unit do you use for vacuum
assisted (mammotome) breast biopsies?
4. What gauge needle do you use for vacuum assisted (mammotome) breast biopsy?
Procedure
The information in this section relates to DIAGNOSTIC procedures only.
The information required in this section refers to activities undertaken in your service between
January and December 2001.
1. In 2001 how many women were screened through your service?
2. In 2001, of all the women screened at your service how many were recalled for investigation 
of a micro-calcification?
3. In 2001, of all women with a detected micro-calcification abnormality, how many went on to have
the initial investigation of the micro-calcification performed by:  
- stereotactic vacuum assisted (mammotome) breast biopsy:
- stereotactic core biopsy:
- other (please specify):
18
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Please complete for stereotactic assessment of microcalcifications only
TYPE OF  DEFINITIVE INADEQUATE/INDETERMINATE/ TOTAL
PROCEDURE OUTCOME SUSPICIOUS (CODES 3 & 4)
NORMAL OR  MALIGNANT RE-BIOPSY RE-BIOPSY OPEN 
BENIGN  (CODE 5) – STEREO – STEREO  BIOPSY






c) Of all woman who had a vacuum assisted (mammotome) breast biopsy, how many had
Micromark clips inserted?
d) How many Micromark clips in total were inserted in your clinic in 2001?
Staff required for procedures 
In Table 1, please specify all staff needed to undertake stereotactic core and vacuum assisted
(mammotome) breast biopsy. Please include staff and time involved in ‘setting up’ for each
procedure.
> Column 1: List all the staff required per core biopsy and vacuum assisted (mammotome) breast
biopsy (eg. procedures nurse, radiographer, radiologist, counsellor).
> Column 2: Number of staff required.
> Column 3: Level of staff qualification (if required).
> Column 4: Estimate of staff time required by each staff member per procedure.
Table 1. Staff required for stereotactic core biopsy and vacuum assisted (mammotome)
breast biopsy.











Other1 Did staff need to be specifically trained to use the vacuum assisted (mammotome) breast biopsy
system? If YES, how much time was involved in training?
General questions about the vacuum assisted (mammotome) breast biopsy and
stereotactic core biopsy
1E s timate the total time taken to perform a:
- Stereotactic core biopsy:
- Stereotactic vacuum assisted (mammotome) breast biopsy:
2 Specify all routine pathology tests undertaken for those women who have stereotactic vacuum
assisted (mammotome) breast biopsy.
3 Specify all routine pathology tests undertaken for those women who have a stereotactic core
biopsy.
4P l ease outline all patient consumables (eg. gloves, bandages anaesthetic etc), machine
consumables (eg. needle, saline, syringe) and patient non-disposables (eg. forceps, instrument
pack etc.) associated with vacuum assisted (mammotome) breast biopsy and stereotactic core
biopsy in Table 2 (see next page). 
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Instructions for filling out the Table 2 are as follows:
> Column 1: A preliminary list of consumables associated with vacuum assisted (mammotome)
breast biopsy is provided. 
> Column 2: Indicate how many of these items are used per procedure. If you do not use an item
listed indicate this with N/A. 
>If your service uses items not listed, list them under ‘other’ at the end of the table.
> Column 3: Indicate whether the item listed is disposable (D) or non-disposable (ND) 
> Column 4: List all consumables used for each stereotactic core biopsy. 
> Column 5: Indicate the number of items used per stereotactic core biopsy
> Column 6: Indicate whether the item is disposable (D) or non-disposable (ND) 
Table 2. Consumables associated with stereotactic core and vacuum assisted
(mammotome) breast biopsy
VACUUM ASSISTED NUMBER OF DISPOSABLE OR CORE BREAST NUMBER OF  DISPOSABLE OR
(MAMMOTOME) ITEMS USED NON-DISPOSABLE BIOPSY ITEMS USED NON-DISPOSABLE





































Micromark slideTable 2. Consumables associated with stereotactic core and vacuum assisted
(mammotome) breast biopsy (continued)
VACUUM ASSISTED NUMBER OF DISPOSABLE OR CORE BREAST NUMBER OF  DISPOSABLE OR 
(MAMMOTOME) ITEMS USED NON-DISPOSABLE BIOPSY ITEMS USED NON-DISPOSABLE





















Syringe, slip, 10 ml
Other
If more room is required please continue on back of this page.
Thank you for completing this survey.
Please return it to CHERE in the reply-paid envelope.
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APPENDIX 3 – REMINDER LETTER
22 October 2002
Dear Director,
Recently you received a request from the National Breast Cancer Centre and the Centre for Health
Economics Research and Evaluation (CHERE) to fill out a survey which sought information on the
use of  vacuum assisted breast biopsy in your centre. The information collected from this survey is to
be used in a study to assess the cost effectiveness of vacuum assisted breast biopsy. If you have
already returned your survey please ignore this letter.
If you have not returned your survey, either because you did not receive this survey, were unable to
complete the survey for some reason, or simply need more time to complete the survey could you
please let either Marion Haas (02) 9351 0908 or Lorraine Ivancic (02) 9351 0919 know. Your
cooperation is greatly appreciated.
Yours sincerely,
Marion Haas
Deputy Director CHEREAPPENDIX 4
Study background
This aim of this study is to assess the cost-effectiveness of stereotactic vacuum assisted breast
biopsy in the diagnosis of microcalcifications. In this study the cost-effectiveness of vacuum assisted
(mammotome) breast biopsy will be compared against standard stereotactic core biopsy.  
The information in this questionnaire relates to standard stereotactic core biopsy (ie. exclude any
vacuum assisted procedures) in the diagnosis of microcalcifications.
Procedure: Standard stereotactic core biopsy
The information required in this section refers to activities undertaken in your service between
January and December 2001.
1. In 2001 how many women were screened through your service?
2. In 2001, of all the women screened at your service how many were recalled for investigation 
of a micro-calcification?
3.  In 2001, of all women with a detected micro-calcification abnormality, how many went on to have
the initial investigation of the micro-calcification performed by:  
- standard stereotactic core biopsy:
- other (please specify):
Please complete for standard stereotactic assessment of microcalcifications only
TYPE OF  DEFINITIVE OUTCOME INADEQUATE/INTEDERMINITE/ TOTAL
PROCEDURE SUSPICIOUS (CODES 3 & 4)
NORMAL OR  MALIGNANT RE-BIOPSY OPEN BIOPSY




Staff required for procedures 
In Table 1 (see next page) specify all staff needed to undertake standard stereotactic core biopsy.
Please include staff and time involved in ‘setting up’ for each procedure.
> Column 1:  List all the staff required per core biopsy (eg. procedures nurse, radiographer,
radiologist, counsellor).
> Column 2:  Number of staff required.
> Column 3:  Level of staff qualification (if required).
> Column 4:  Estimate of staff time required by each staff member per procedure.
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1. Did staff need to be specifically trained to undertake standard core biopsies? If YES, how much
time was involved in training?
General questions on standard stereotactic core biopsy
1. Estimate the total time taken to perform a standard stereotactic core biopsy (in minutes).
2. Specify all routine pathology tests undertaken for those women who have a standard stereotactic
core biopsy.
3. All patient consumables (eg. gloves, bandages anaesthetic etc), machine consumables (eg.
needle, saline, syringe) and patient non-disposables (eg. forceps, instrument pack etc.)
associated with standard stereotactic core biopsy are to be outlined in Table 2 (see next page).
Instructions for filling out the table are as follows:
> Column 1: A preliminary list of consumables associated with standard stereotactic core 
biopsy is provided. 
> Column 1: Indicate how many of these items are used per procedure. If you do not use an item
listed indicate this with N/A. 
If your service uses items not listed, list them under ‘other’ at the end of the table.
> Column 1: Indicate whether the item listed is disposable (D) or non-disposable (ND)
25
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STEREOTACTIC STANDARD  NUMBER OF ITEMS DISPOSABLE OR




Dressing, wound op site 
(specify size)
Forms (please specify type 





Gauze swab, sterile (specify size)
Gloves







Pamphlets (please specify 


















If more room is required please continue on back of this page.
Thank you for completing this survey.
Please return it to CHERE in the reply-paid envelope 
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